Spanish National Cancer Research Centre CNIO

A team of US researchers has followed some patients treated with CAR-T therapies in a small clinical trial conducted between 2004 and 2009 to treat children with neuroblastoma, a nerve cell tumor that can have a poor prognosis. At least one of them, a woman who was treated with CAR-T as a child, remains in remission 18 years later, the longest duration of such therapy described to date. The results are published in the journal Nature Medicine. 

CAR-T cell-based treatments have been successful against some blood tumours, but are much less effective for solid tumours. A phase 1 clinical trial has tested their use in 11 children and young adults with diffuse midline glioma, a tumour of the nervous system that is considered incurable. The results, published in the journal Nature, indicate that the treatment improved functional status in nine of the 11 patients. One of the four who showed a strong response is still healthy four years later.

The Royal Swedish Academy of Sciences has awarded the Nobel Prize in Chemistry 2024 on the one hand to David Baker for computational protein design, which makes it possible to construct proteins with functions not present in nature. On the other hand, jointly to Demis Hassabis and John M. Jumper of Google DeepMind, for the development of AlphaFold2, which allows the structure of the 200 million known proteins to be predicted at high speed. 

If you're traveling to –or from– distant lands, this brief guide can help you minimize the effects of the time difference, the feared jet lag, so you can enjoy your vacation more (or go back to the routine less harshly).

In a paper published in Molecular Cell, a team of researchers led by the Spanish National Cancer Research Centre (CNIO) provides the first evidence that a possible cause of the hereditary type of ALS - familial ALS - is the accumulation in motor neurons of 'junk proteins', proteins with no function that accumulate unduly and prevent the cell from functioning properly. In addition, the research describes a new causal factor in the ageing process: nucleolar stress, which encompasses alterations in organelles called nucleoli. 

A fatty acid present in the meat and dairy products of grazing animals, such as cows and sheep – trans-vaccenic acid (TVA) – enhances the ability of CD8+ T cells to infiltrate tumors and eliminate cancer cells, according to a new study conducted by researchers from the University of Chicago (USA), published today in the journal Nature.

Klotho is a protein whose concentrations tend to decline with age and which has been linked to ageing processes. Now, researchers have found that administration of the protein improves cognitive function in aged rhesus macaques, including benefits in spatial and working memory. According to the authors, who publish the results in the journal Nature Aging, its use "may be therapeutic in humans".

Taurine is one of the most abundant amino acids in animals. As reported in research published in Science, its loss may contribute to the ageing process. According to the study, reversing age-associated taurine deficiency through supplementation improved life expectancy in worms and rodents, while improving some health parameters in non-human primates, which the authors believe would warrant further human trials to examine its effect on life expectancy and the potential risks involved.

Researchers have shown that hypoxia, or oxygen restriction - equivalent to living at 5,000 metres above sea level - increases life expectancy by up to 50% and decreases neurological decline in laboratory mice. It has already been shown in yeast, worms and flies, but this is the first time it has been demonstrated in mammals. The results are published in the journal PLOS Biology. 

A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).